← Back to Search

FLT-PET for Neuroblastoma

N/A
Waitlist Available
Led By Anthony F. Shields, M.D., Ph.D.
Research Sponsored by Barbara Ann Karmanos Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3rd pet: 6-15 wks (prior to surgery)
Awards & highlights

Study Summary

The purpose of this study is to gain knowledge about how to best diagnose and treat tumors, how tumors affect normal tissue and how treatment of tumors with radiation therapy and chemotherapy affect tumors.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3rd pet: 6-15 wks (prior to surgery)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3rd pet: 6-15 wks (prior to surgery) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To determine whether 18F-FLT-PET is a sensitive tool to image neuroblastoma.
Secondary outcome measures
To evaluate the utility of FLT-PET in early assessment of patient response to
To evaluate the utility of FLT-PET in early assessment of patient response to treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: FLT-PETExperimental Treatment1 Intervention
Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment. Low risk patients: observation only. Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection. High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin. PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FLT-PET
2015
Completed Phase 1
~130

Find a Location

Who is running the clinical trial?

Barbara Ann Karmanos Cancer InstituteLead Sponsor
163 Previous Clinical Trials
9,206 Total Patients Enrolled
2 Trials studying Neuroblastoma
63 Patients Enrolled for Neuroblastoma
Children's Hospital of MichiganOTHER
25 Previous Clinical Trials
4,243 Total Patients Enrolled
1 Trials studying Neuroblastoma
23 Patients Enrolled for Neuroblastoma
Anthony F. Shields, M.D., Ph.D.Principal InvestigatorBarbara Ann Karmanos Cancer Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)
Zhihong Wang 2011. "Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01308905.
All > Flu
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top